The drug, known as AP-2, is a product of a decade of preclinical scrutiny. It does not merely mask the symptoms of Amyotrophic Lateral Sclerosis; it is designed to enter the cellular fray. By blocking the inflammatory reactions that accelerate the death of motor neurons, the treatment aims to prevent the accumulation of abnormal proteins that characterize the disease. These neurons are among the most remarkable structures in the human body, possessing single axons that can reach over a meter in length, stretching from the spine to the furthest reaches of a foot.
For Dr. Javier Vaquero, the trial is the culmination of a long-held professional conviction. While current standard treatments like Riluzole offer only a brief extension of life, this new pharmacological approach seeks to stimulate the body’s own neuroprotection mechanisms. The 72 patients enrolled in this Phase I study will receive the drug intravenously, with the primary goal of establishing its safety and pharmacological behavior before moving to broader efficacy trials.
The recruitment of participants began this spring, with the first intravenous treatments scheduled for May 2026. For María, the timing is measured not in clinical quarters or fiscal years, but in the domestic milestones of a grandmother. Her diagnosis is sporadic, appearing without the warning of family history, a common trait in nearly 95 percent of all cases.
Her hope is precise and devoid of grandiosity: she wishes for the drug to slow the erosion of her strength just enough to remain present for her grandchildren. As the medical team monitors the first 72 volunteers, the data they gather will determine if the trial can proceed to Phase II by early 2028. Behind the sterile precision of the trial protocols lies this simple, human ambition—to stay a little longer in the light of the living.